IBRX Rises as Director Linda Maxwell Adds Another Board Seat After HLS Appointment
IBRX is in focus after Linda Maxwell’s expanded board footprint highlights her leadership roles
ImmunityBio, Inc. (NASDAQ:IBRX) traded at $10.40 as of 11:36 AM during market hours, up $1.12 (12.07%). Attention around the ticker followed a press release from HLS Therapeutics Inc. (TSX:HLS) announcing board of directors changes that include the appointment of Linda Maxwell, M.D. as an independent director.
While the announcement was issued by HLS (not ImmunityBio), the release specifically notes that Dr. Maxwell is already a director of ImmunityBio, where she chairs the Compensation Committee and also serves on the Audit and Related Party Transactions committees. The new HLS role adds to a set of governance responsibilities across multiple public-company boards.
The press release ties Maxwell’s experience to audit oversight and growth planning, with IBRX cited as a key governance role
In its Oct. 1, 2026 announcement, HLS Therapeutics said it appointed Linda Maxwell, M.D. and Mark DeLong as independent directors, effective immediately, following the departures of Dr. Kyle Dempsey and Christine Elliott. After the changes, HLS said its board consists of eight directors, with six independent.
HLS stated that Dr. Maxwell will join its Audit Committee. In the release, HLS Chair John Welborn said Dr. Maxwell’s “medical expertise, healthcare entrepreneurship and public-company audit experience” would add depth to assessing growth opportunities and financial oversight. The same press release identifies Dr. Maxwell’s current board roles, including at ImmunityBio (NASDAQ:IBRX) and United Therapeutics (NASDAQ:UTHR), and notes she is an Operating Partner at DCVC.
| Company Mentioned | Role Named in the Release | Committee Responsibilities Cited |
|---|---|---|
| ImmunityBio, Inc. (NASDAQ:IBRX) | Director (Linda Maxwell, M.D.) | Chair: Compensation Committee; Member: Audit and Related Party Transactions Committees |
| HLS Therapeutics Inc. (TSX:HLS) | Appointed Independent Director (Linda Maxwell, M.D.) | Joining: Audit Committee |
| United Therapeutics Corporation (NASDAQ:UTHR) | Director (Linda Maxwell, M.D.) | Member: Compensation; Nominating and Governance Committees |
HLS board restructuring emphasizes independence, with IBRX referenced through Maxwell’s committee leadership
HLS framed the board refresh as part of positioning the company for its “next phase of growth.” The company highlighted both new appointees’ backgrounds, and it also detailed the outgoing directors’ transitions: Dr. Dempsey stepped down after four years of service, while Ms. Elliott stepped down and is returning to a consulting role with HLS focused on healthcare policy and government relations.
For IBRX watchers, the notable element is that the release explicitly calls out Dr. Maxwell’s committee leadership at ImmunityBio—specifically her role chairing the Compensation Committee and serving on audit-related committees—while also placing her on HLS’s Audit Committee. That pairing underlines a consistent governance theme: financial oversight and board-level accountability.
IBRX price snapshot: shares were higher during market hours as of 11:36 AM
| Ticker | Price (11:36 AM) | Change | % Change |
|---|---|---|---|
| IBRX | $10.40 | $1.12 | 12.07% |
Forward-looking language in the release underscores uncertainty even as boards plan for growth
HLS included standard forward-looking statement language noting that expectations about growth opportunities, financial performance, and other strategic initiatives may differ materially due to risks and uncertainties. Although this disclosure is specific to HLS, it serves as a reminder that board and committee appointments often accompany long-horizon planning rather than near-term operational changes.
Bottom line for IBRX readers: the press release does not announce changes at ImmunityBio itself, but it does spotlight a key IBRX director’s expanding responsibilities—specifically, Dr. Maxwell’s audit-oriented governance roles across multiple public companies.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI